Literature DB >> 15061198

Prognostic significance of surface markers expressed in multiple myeloma: CD56 and other antigens.

Naohi Sahara1, Akihiro Takeshita.   

Abstract

Multiple myeloma (MM) is characterized by increased numbers of malignant plasma cells. Plasma cells, that represent the terminal differentiation of B lymphocytes, have considerable heterogeneity of surface markers expressed on them. Some studies showed the prognostic significance of several immunophenotypic molecules on MM cells. Here, we review several surface markers related to their prognostic significance in MM patients. We also report that CD56-negative MM is the unique entity characterized by poor prognosis with high incidence of extramedullary disease, Bence Jones protein, renal insufficiency, thrombocytopenia and plasmablastic morphology.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15061198     DOI: 10.1080/1042819031000149377

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  15 in total

Review 1.  The microenvironment in mature B-cell malignancies: a target for new treatment strategies.

Authors:  Jan A Burger; Paolo Ghia; Andreas Rosenwald; Federico Caligaris-Cappio
Journal:  Blood       Date:  2009-07-27       Impact factor: 22.113

Review 2.  Diagnosis of Plasma Cell Dyscrasias and Monitoring of Minimal Residual Disease by Multiparametric Flow Cytometry.

Authors:  Kah Teong Soh; Joseph D Tario; Paul K Wallace
Journal:  Clin Lab Med       Date:  2017-12       Impact factor: 1.935

3.  Clinical effect of immunophenotyping on the prognosis of multiple myeloma patients treated with bortezomib.

Authors:  Noriyoshi Iriyama; Katsuhiro Miura; Yoshihiro Hatta; Sumiko Kobayashi; Yoshihito Uchino; Daisuke Kurita; Hitomi Sakagami; Hiromichi Takahashi; Masashi Sakagami; Yujin Kobayashi; Masaru Nakagawa; Shimon Ohtake; Yoshikazu Iizuka; Masami Takei
Journal:  Oncol Lett       Date:  2017-03-27       Impact factor: 2.967

4.  The maturation of myeloma cells correlates with sensitivity to chemotherapeutic agents.

Authors:  Yoshiaki Kuroda; Akira Sakai; Yoshiko Okikawa; Shoso Munemasa; Yuta Katayama; Hideo Hyodo; Jun Imagawa; Yasuo Takimoto; Hajime Okita; Megu Ohtaki; Akiro Kimura
Journal:  Int J Hematol       Date:  2005-05       Impact factor: 2.490

5.  Fatal cerebral hemorrhage in a patient with CD19-positive IgM-producing aggressive plasma cell myeloma, hyperviscosity syndrome and cryoglobulinemia.

Authors:  Adnan Alatoom; Rania Elsabrouty; Jason Willis; Christie Boils; Ravindra Sarode; Ibrahim Hashim; Huan-You Wang
Journal:  Int J Clin Exp Pathol       Date:  2009-02-09

6.  Multiples aberrant phenotypes in multiple myeloma patient expressing CD56(-), CD28(+),CD19(+).

Authors:  Luiz Arthur Calheiros Leite; Daniela Márcia Bahia Kerbauy; Elisa Kimura; Mihoko Yamamoto
Journal:  Rev Bras Hematol Hemoter       Date:  2012

7.  Small-lymphoid cells and myeloid antigen expression in a patient with IgG myeloma: A case report.

Authors:  Pengjun Jiang; Wen Xia; Xuemei Sun; Xingbin Dai; Lin Li
Journal:  Oncol Lett       Date:  2016-02-08       Impact factor: 2.967

8.  Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma.

Authors:  Martin F Kaiser; David C Johnson; Ping Wu; Brian A Walker; Annamaria Brioli; Fabio Mirabella; Christopher P Wardell; Lorenzo Melchor; Faith E Davies; Gareth J Morgan
Journal:  Blood       Date:  2013-05-22       Impact factor: 22.113

9.  Immunohistochemical evaluation of 95 bone marrow reactive plasmacytoses.

Authors:  Maria G Ioannou; Efstathios Stathakis; Andreas C Lazaris; Thomas Papathomas; Evangelos Tsiambas; George K Koukoulis
Journal:  Pathol Oncol Res       Date:  2008-06-14       Impact factor: 3.201

Review 10.  Association of Chromosomal Translocation and MiRNA Expression with The Pathogenesis of Multiple Myeloma.

Authors:  Najmaldin Saki; Saeid Abroun; Saeideh Hajizamani; Fakher Rahim; Mohammad Shahjahani
Journal:  Cell J       Date:  2014-05-25       Impact factor: 2.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.